Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk Not Deterred By Regulatory Hurdles For Diabetes Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA cardiovascular requirements for Victoza will be met post approval, management predicts.

You may also be interested in...



UnitedHealth’s PBM Director Scans The 2009 Pharmaceutical Horizon

Pharmacy benefit managers face challenges in preparing their health plans for new product launches in 2009, given the increasingly unpredictable competitive environment for pharmaceuticals. A "nervous" FDA, fewer patents expiring for brand name drugs, and high barriers to developing truly better drugs have led to systemic bottlenecks in the availability of new products, and none of these factors are going away anytime soon

UnitedHealth’s PBM Director Scans The 2009 Pharmaceutical Horizon

Pharmacy benefit managers face challenges in preparing their health plans for new product launches in 2009, given the increasingly unpredictable competitive environment for pharmaceuticals. A "nervous" FDA, fewer patents expiring for brand name drugs, and high barriers to developing truly better drugs have led to systemic bottlenecks in the availability of new products, and none of these factors are going away anytime soon

Amylin Speculation Intensifies: Byetta LAR May Be Delayed

Comparability studies could mean filing is impossible for first half of 2009, Amylin says.

Related Content

Topics

UsernamePublicRestriction

Register

PS066967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel